300003 乐普医疗
已收盘 11-09 15:00:00
资讯
新帖
简况
乐普医疗（300003）11月6日主力资金净卖出1038.22万元
证券之星 · 09:45
乐普医疗（300003）11月6日主力资金净卖出1038.22万元
乐普医疗获得发明专利授权：“血管内径测量方法和装置、存储介质”
证券之星 · 11-07 11:52
乐普医疗获得发明专利授权：“血管内径测量方法和装置、存储介质”
研报掘金｜东方证券：维持乐普医疗“买入”评级，利润短期承压，新兴业务持续推进
格隆汇 · 10-30
研报掘金｜东方证券：维持乐普医疗“买入”评级，利润短期承压，新兴业务持续推进
乐普医疗（300003）2026年三季报简析：净利润同比下降30.93%，公司应收账款体量较大
证券之星 · 10-25
乐普医疗（300003）2026年三季报简析：净利润同比下降30.93%，公司应收账款体量较大
乐普医疗（300003）披露2026年三季度报告，10月23日股价上涨2.25%
证券之星 · 10-23
乐普医疗（300003）披露2026年三季度报告，10月23日股价上涨2.25%
乐普医疗(300003)9月30日股东户数10.27万户，较上期减少1.16%
证券之星 · 10-23
乐普医疗(300003)9月30日股东户数10.27万户，较上期减少1.16%
乐普医疗最新公告：前三季度净利润同比下降30.93%
证券之星 · 10-23
乐普医疗最新公告：前三季度净利润同比下降30.93%
乐普医疗（300003）10月22日主力资金净买入2110.05万元
证券之星 · 10-23
乐普医疗（300003）10月22日主力资金净买入2110.05万元
乐普医疗（300003）10月21日主力资金净买入4473.57万元
证券之星 · 10-22
乐普医疗（300003）10月21日主力资金净买入4473.57万元
乐普医疗（300003）10月13日主力资金净卖出1647.04万元
证券之星 · 10-14
乐普医疗（300003）10月13日主力资金净卖出1647.04万元
乐普医疗最新公告：子公司MWN117注射液获美国FDA临床试验批准
证券之星 · 10-08
乐普医疗最新公告：子公司MWN117注射液获美国FDA临床试验批准
乐普医疗（300003）9月30日主力资金净买入795.67万元
证券之星 · 10-08
乐普医疗（300003）9月30日主力资金净买入795.67万元
乐普医疗最新公告：子公司MWN110注射液获美国FDA临床试验批准
证券之星 · 09-28
乐普医疗最新公告：子公司MWN110注射液获美国FDA临床试验批准
公司问答丨乐普医疗：三文鱼针目前正处于国家药品监督管理局的审评审批阶段 尚未取得正式注册批件
格隆汇 · 09-14
公司问答丨乐普医疗：三文鱼针目前正处于国家药品监督管理局的审评审批阶段 尚未取得正式注册批件
公司问答丨乐普医疗：候选药物MWN109注射液超重、肥胖适应症已完成II期临床试验 预计将在2026年内启动入组工作
格隆汇 · 09-14
公司问答丨乐普医疗：候选药物MWN109注射液超重、肥胖适应症已完成II期临床试验 预计将在2026年内启动入组工作
公司问答丨乐普医疗：赛乐提产品目前已经开始产生销售 正积极推进该产品的商业化工作
格隆汇 · 09-14
公司问答丨乐普医疗：赛乐提产品目前已经开始产生销售 正积极推进该产品的商业化工作
乐普医疗旗下APP被通报 违法违规收集使用个人信息
中金财经 · 09-07
乐普医疗旗下APP被通报 违法违规收集使用个人信息
乐普医疗上半年净利暴跌超30％，核心产品遭欧洲四国禁售
微博财经-财道工作室 · 08-31
乐普医疗上半年净利暴跌超30％，核心产品遭欧洲四国禁售
股市必读：乐普医疗（300003）8月25日披露最新机构调研信息
证券之星 · 08-26
股市必读：乐普医疗（300003）8月25日披露最新机构调研信息
乐普医疗（300003）2026年中报简析：净利润同比下降27.71%，公司应收账款体量较大
证券之星 · 08-23
乐普医疗（300003）2026年中报简析：净利润同比下降27.71%，公司应收账款体量较大
加载更多
公司概况
公司名称：
乐普(北京)医疗器械股份有限公司
所属行业：
专用设备制造业
上市日期：
2009-10-30
主营业务：
乐普(北京)医疗器械股份有限公司的主营业务是医疗器械及其配件的技术开发、生产，销售。公司的主要产品是医疗器械、药品、医疗服务、健康管理。公司作为国内最早研发心血管植介入器械的企业之一，拥有国家科技部授予的“国家心脏病植介入诊疗器械及装备工程技术研究中心”称号。
发行价格：
29.00
{"stockData":{"symbol":"300003","market":"SZ","secType":"STK","nameCN":"乐普医疗","latestPrice":12.4,"timestamp":1794207783000,"preClose":12.61,"halted":0,"volume":18757600,"delay":0,"changeRate":-0.0167,"floatShares":1579000000,"shares":1843000000,"eps":0.3571,"marketStatus":"已收盘","change":-0.21,"latestTime":"11-09 15:00:00","open":12.64,"high":12.85,"low":12.39,"amount":236000000,"amplitude":0.0365,"askPrice":12.4,"askSize":251,"bidPrice":12.39,"bidSize":1051,"shortable":0,"etf":0,"ttmEps":0.3571,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794274200000},"marketStatusCode":5,"adr":0,"adjPreClose":12.61,"symbolType":"stock","openAndCloseTimeList":[[1794187800000,1794195000000],[1794200400000,1794207600000]],"highLimit":13.87,"lowLimit":11.35,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1843424716,"isCdr":false,"pbRate":1.42,"roa":"--","peRate":34.724167,"roe":"4.13%","epsLYR":0.5219,"committee":0.178767,"marketValue":22858000000,"turnoverRate":0.0119,"status":1,"floatMarketCap":19579000000},"requestUrl":"/m/hq/s/300003","defaultTab":"news","newsList":[{"id":"2682827123","title":"乐普医疗（300003）11月6日主力资金净卖出1038.22万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2682827123","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682827123?lang=zh_cn&edition=full","pubTime":"2026-11-09 09:45","pubTimestamp":1794188748,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月6日收盘，乐普医疗报收于12.61元，上涨0.24%，换手率1.63%，成交量25.8万手，成交额3.27亿元。近5日资金流向一览见下表：乐普医疗融资融券信息显示，融资方面，当日融资买入2271.96万元，融资偿还2304.58万元，融资净偿还32.62万元。融券方面，融券卖出1.37万股，融券偿还9100.0股，融券余量69.63万股，融券余额878.03万元。乐普医疗主营业务：提供心血管疾病领域全生命周期的整体解决方案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110900002392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300003","BK0188","BK0196","BK0201","BK0251","BK0114","BK0113","BK0042","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681816344","title":"乐普医疗获得发明专利授权：“血管内径测量方法和装置、存储介质”","url":"https://stock-news.laohu8.com/highlight/detail?id=2681816344","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681816344?lang=zh_cn&edition=full","pubTime":"2026-11-07 11:52","pubTimestamp":1794023550,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示乐普医疗新获得一项发明专利授权，专利名为“血管内径测量方法和装置、存储介质”，专利申请号为CN202211474845.5，授权日为2026年11月6日。今年以来乐普医疗新获得专利授权22个，较去年同期增加了46.67%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110700012073.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0042","300003","BK0196","BK0251","BK0113","BK0114","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679026297","title":"研报掘金｜东方证券：维持乐普医疗“买入”评级，利润短期承压，新兴业务持续推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2679026297","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679026297?lang=zh_cn&edition=full","pubTime":"2026-10-30 15:36","pubTimestamp":1793345772,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["300003","BK0113","BK0042","BK0183","BK0188","BK0251","BK0196","BK0201","BK0012","600958","BK0114","BK0276","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678412185","title":"乐普医疗（300003）2026年三季报简析：净利润同比下降30.93%，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2678412185","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678412185?lang=zh_cn&edition=full","pubTime":"2026-10-25 06:10","pubTimestamp":1792879834,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期乐普医疗发布2026年三季报。截至本报告期末，公司营业总收入46.27亿元，同比下降6.32%，归母净利润6.78亿元，同比下降30.93%。按单季度数据看，第三季度营业总收入14.13亿元，同比下降9.99%，第三季度归母净利润1.79亿元，同比下降38.58%。本报告期乐普医疗公司应收账款体量较大，当期应收账款占最新年报归母净利润比达245.19%。本文数据来源于乐普医疗2026年三季报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102500000666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300003"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677973692","title":"乐普医疗（300003）披露2026年三季度报告，10月23日股价上涨2.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677973692","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677973692?lang=zh_cn&edition=full","pubTime":"2026-10-23 22:38","pubTimestamp":1792766301,"startTime":"0","endTime":"0","summary":"截至2026年10月23日收盘，乐普医疗报收于12.29元，较前一交易日上涨2.25%，最新总市值为226.56亿元。该股当日开盘11.95元，最高12.31元，最低11.9元，成交额达3.86亿元，换手率为2.02%。报告显示，2026年第三季度营业收入1,412,531,810.99元，同比下降9.99%；归属于上市公司股东的净利润178,812,983.57元，同比下降38.58%。年初至报告期末营业收入4,626,725,903.30元，同比下降6.32%；归属于上市公司股东的净利润678,288,593.36元，同比下降30.93%。经营活动产生的现金流量净额854,098,002.44元，同比下降15.66%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300045777.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300003","BK0188","BK0201","BK0113","BK0251","BK0114","BK0028","BK0196","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677928188","title":"乐普医疗(300003)9月30日股东户数10.27万户，较上期减少1.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677928188","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677928188?lang=zh_cn&edition=full","pubTime":"2026-10-23 17:59","pubTimestamp":1792749568,"startTime":"0","endTime":"0","summary":"证券之星消息，近日乐普医疗披露，截至2026年9月30日公司股东户数为10.27万户，较6月30日减少1206.0户，减幅为1.16%。在医疗器械行业个股中，乐普医疗股东户数高于行业平均水平，截至9月30日，医疗器械行业平均股东户数为2.06万户。从股价来看，2026年6月30日至2026年9月30日，乐普医疗区间跌幅为1.6%，在此期间股东户数减少1206.0户，减幅为1.16%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300032858.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0042","300003","BK0196","BK0251","BK0113","BK0114","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677940989","title":"乐普医疗最新公告：前三季度净利润同比下降30.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677940989","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677940989?lang=zh_cn&edition=full","pubTime":"2026-10-23 17:38","pubTimestamp":1792748329,"startTime":"0","endTime":"0","summary":"乐普医疗(300003.SZ)公告称，第三季度实现营业收入14.13亿元，同比下降9.99%；归属于上市公司股东的净利润1.79亿元，同比下降38.58%。前三季度实现营业收入46.27亿元，同比下降6.32%；归属于上市公司股东的净利润6.78亿元，同比下降30.93%。业绩变动主要系报告期内可转债到期赎回所致一次性支出增加9821.06万元，研发费用同比增加1.24亿元，两项合计2.22亿元所致。注：公司Q3净利润1.79亿，Q2净利润2.53亿，据此计算，Q3净利润环比下降29%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300032048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300003"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677915851","title":"乐普医疗（300003）10月22日主力资金净买入2110.05万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677915851","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677915851?lang=zh_cn&edition=full","pubTime":"2026-10-23 09:05","pubTimestamp":1792717554,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月22日收盘，乐普医疗报收于12.02元，上涨0.92%，换手率3.03%，成交量47.88万手，成交额5.83亿元。近5日资金流向一览见下表：乐普医疗融资融券信息显示，融资方面，当日融资买入3374.28万元，融资偿还4920.86万元，融资净偿还1546.58万元。乐普医疗主营业务：提供心血管疾病领域全生命周期的整体解决方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300009120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0113","BK0114","BK0201","BK0028","BK0196","BK0042","300003","BK0188","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677989701","title":"乐普医疗（300003）10月21日主力资金净买入4473.57万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677989701","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677989701?lang=zh_cn&edition=full","pubTime":"2026-10-22 09:05","pubTimestamp":1792631127,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月21日收盘，乐普医疗报收于11.91元，上涨4.2%，换手率2.51%，成交量39.65万手，成交额4.68亿元。近5日资金流向一览见下表：乐普医疗融资融券信息显示，融资方面，当日融资买入2863.61万元，融资偿还3844.64万元，融资净偿还981.03万元。乐普医疗主营业务：提供心血管疾病领域全生命周期的整体解决方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200007867.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300003","BK0201","BK0113","BK0251","BK0188","BK0114","BK0028","BK0042","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675399660","title":"乐普医疗（300003）10月13日主力资金净卖出1647.04万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675399660","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675399660?lang=zh_cn&edition=full","pubTime":"2026-10-14 09:17","pubTimestamp":1791940675,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月13日收盘，乐普医疗报收于11.5元，下跌1.88%，换手率1.0%，成交量15.78万手，成交额1.81亿元。近5日资金流向一览见下表：乐普医疗融资融券信息显示，融资方面，当日融资买入1726.34万元，融资偿还1225.14万元，融资净买入501.2万元。乐普医疗主营业务：提供心血管疾病领域全生命周期的整体解决方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400008472.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0042","BK0114","BK0113","BK0196","BK0188","300003","BK0201","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673007640","title":"乐普医疗最新公告：子公司MWN117注射液获美国FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2673007640","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673007640?lang=zh_cn&edition=full","pubTime":"2026-10-08 18:41","pubTimestamp":1791456064,"startTime":"0","endTime":"0","summary":"乐普医疗(300003.SZ)公告称，公司控股子公司上海民为生物技术有限公司获得美国FDA关于同意MWN117注射液开展临床试验的通知书。该药品为靶向抑制INHBE的siRNA药物，适应症为超重或肥胖，目前已获CDE临床试验批准。非临床研究显示，该药物单用或与GLP-1受体激动剂联用均能有效降低体重和体脂，同时减少肌肉流失，药效持续至12周。目前国内外尚无同类药物获批上市。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800027444.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0114","300003","BK0251","BK0196","BK0201","BK0113","BK0042","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673041817","title":"乐普医疗（300003）9月30日主力资金净买入795.67万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2673041817","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673041817?lang=zh_cn&edition=full","pubTime":"2026-10-08 09:09","pubTimestamp":1791421779,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月30日收盘，乐普医疗报收于11.66元，上涨2.37%，换手率1.11%，成交量17.58万手，成交额2.04亿元。近5日资金流向一览见下表：乐普医疗融资融券信息显示，融资方面，当日融资买入1883.07万元，融资偿还4111.8万元，融资净偿还2228.73万元。乐普医疗主营业务：提供心血管疾病领域全生命周期的整体解决方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800003049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0113","BK0251","BK0114","300003","BK0201","BK0042","BK0028","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670239542","title":"乐普医疗最新公告：子公司MWN110注射液获美国FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2670239542","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670239542?lang=zh_cn&edition=full","pubTime":"2026-09-28 18:40","pubTimestamp":1790592009,"startTime":"0","endTime":"0","summary":"乐普医疗(300003.SZ)公告称，公司控股子公司上海民为生物获得美国FDA关于同意MWN110注射液开展临床试验的通知书。该药品为靶向ActRIIA/B的单克隆抗体，申请适应症为超重或肥胖，拥有全球知识产权，已于2026年7月获得CDE临床试验批准。非临床研究显示，该药品单用能显著降低体脂率、体重并增加肌肉量，与司美格鲁肽联用可抑制肌肉流失。目前国内外尚无同类药物获批上市。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800026251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0028","BK0188","BK0114","BK0201","BK0251","300003","BK0196","BK0113"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667654867","title":"公司问答丨乐普医疗：三文鱼针目前正处于国家药品监督管理局的审评审批阶段 尚未取得正式注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2667654867","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667654867?lang=zh_cn&edition=full","pubTime":"2026-09-14 17:16","pubTimestamp":1789377364,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0114","300003","BK0113","BK0188","BK0196","BK0251","BK0201","BK0042","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667013651","title":"公司问答丨乐普医疗：候选药物MWN109注射液超重、肥胖适应症已完成II期临床试验 预计将在2026年内启动入组工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2667013651","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667013651?lang=zh_cn&edition=full","pubTime":"2026-09-14 17:14","pubTimestamp":1789377296,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0028","BK0188","BK0042","300003","BK0201","BK0113","BK0114","BK0196","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667659950","title":"公司问答丨乐普医疗：赛乐提产品目前已经开始产生销售 正积极推进该产品的商业化工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2667659950","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667659950?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:31","pubTimestamp":1789374675,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0042","BK0196","BK0113","BK0201","BK0251","BK0114","300003","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665392350","title":"乐普医疗旗下APP被通报 违法违规收集使用个人信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2665392350","media":"中金财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665392350?lang=zh_cn&edition=full","pubTime":"2026-09-07 14:48","pubTimestamp":1788763687,"startTime":"0","endTime":"0","summary":"中国经济网北京9月7日讯 国家网络安全通报中心微信公众号9月1日发布消息“公安部计算机信息系统安全产品质量监督检验中心检测发现42款违法违规收集使用个人信息的移动应用”。经公安部计算机信息系统安全产品质量监督检验中心检测，42款移动应用存在一项或者多项违法违规收集使用个人信息情况。 其中，《乐普健康》存在以下问题：未经用户同意收集使用个人信息。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/07/20260907506905.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/07/20260907506905.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260907/32361925.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0028","BK0114","300003","BK0251","BK0196","BK0201","BK0113","BK0042","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663070076","title":"乐普医疗上半年净利暴跌超30％，核心产品遭欧洲四国禁售","url":"https://stock-news.laohu8.com/highlight/detail?id=2663070076","media":"微博财经-财道工作室","labels":["policyRegulatory","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663070076?lang=zh_cn&edition=full","pubTime":"2026-08-31 19:05","pubTimestamp":1788174300,"startTime":"0","endTime":"0","summary":"国内遭遇集采的同时，乐普医疗的封堵器产品在海外还面临了“四国”封锁。乐普“产品未在五国销售、不构成实质侵权”的抗辩未被采纳。更具戏剧性的是，乐普在上诉阶段未现场出庭，仅提交书面抗辩材料。药品毛利率为56.59%，同比下滑6.16个百分点。财务费用激增177%此外，乐普医疗财报中最刺眼的数字来自财务费用，上半年高达1.72亿元，同比激增177%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/wbstock/2026-08-31/doc-iniqfkkr8808016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0113","BK0114","BK0201","BK0028","BK0196","BK0042","300003","BK0188","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662544347","title":"股市必读：乐普医疗（300003）8月25日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2662544347","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662544347?lang=zh_cn&edition=full","pubTime":"2026-08-26 04:08","pubTimestamp":1787688495,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘，乐普医疗报收于11.96元，上涨2.13%，换手率1.4%，成交量22.07万手，成交额2.62亿元。民为生物整合安排：民为生物为乐普2023年孵化的创新药企业，上半年近50%研发费用投向创新药；整合至心泰医疗主要基于四方面考量：提升创新药独立估值、适配差异化管理模式与人才机制、利用港股平台增强融资能力、强化对核心研发人员的激励。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600007716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300003","BK0042","BK0196","BK0188","BK0113","BK0201","BK0114","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661212528","title":"乐普医疗（300003）2026年中报简析：净利润同比下降27.71%，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2661212528","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661212528?lang=zh_cn&edition=full","pubTime":"2026-08-23 06:13","pubTimestamp":1787436795,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期乐普医疗发布2026年中报。截至本报告期末，公司营业总收入32.14亿元，同比下降4.61%，归母净利润4.99亿元，同比下降27.71%。本报告期乐普医疗公司应收账款体量较大，当期应收账款占最新年报归母净利润比达243.46%。持有乐普医疗最多的基金为医疗器械ETF永赢，目前规模为38.29亿元，最新净值0.4447，较上一交易日下跌2.22%，近一年下跌20.29%。本文数据来源于乐普医疗2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300001921.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300003"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794232283401,"stockEarnings":[{"period":"1week","weight":0.0465},{"period":"1month","weight":0.0968},{"period":"3month","weight":-0.0267},{"period":"6month","weight":-0.1053},{"period":"1year","weight":-0.2493},{"period":"ytd","weight":-0.18}],"compareEarnings":[{"period":"1week","weight":0.0139},{"period":"1month","weight":-0.0502},{"period":"3month","weight":-0.0738},{"period":"6month","weight":-0.127},{"period":"1year","weight":-0.0895},{"period":"ytd","weight":-0.0805}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"乐普(北京)医疗器械股份有限公司","boardCode":"AI0035","boardName":"专用设备制造业","stockholders":"102745人(较上一季度减少1.16%)","perCapita":"15367股","listingDate":"2009-10-30","address":"北京市昌平区超前路37号","registeredCapital":"184342万元","survey":" 乐普(北京)医疗器械股份有限公司的主营业务是医疗器械及其配件的技术开发、生产，销售。公司的主要产品是医疗器械、药品、医疗服务、健康管理。公司作为国内最早研发心血管植介入器械的企业之一，拥有国家科技部授予的“国家心脏病植介入诊疗器械及装备工程技术研究中心”称号。","listedPrice":29},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"乐普医疗(300003)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供乐普医疗(300003)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"乐普医疗,300003,乐普医疗股票,乐普医疗股票老虎,乐普医疗股票老虎国际,乐普医疗行情,乐普医疗股票行情,乐普医疗股价,乐普医疗股市,乐普医疗股票价格,乐普医疗股票交易,乐普医疗股票购买,乐普医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"乐普医疗(300003)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供乐普医疗(300003)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}